ZA200408777B - Regeneration of endogenous myocardial tissue by induction of neovascularization - Google Patents

Info

Publication number

ZA200408777B

ZA200408777B ZA200408777A ZA200408777A ZA200408777B ZA 200408777 B ZA200408777 B ZA 200408777B ZA 200408777 A ZA200408777 A ZA 200408777A ZA 200408777 A ZA200408777 A ZA 200408777A ZA 200408777 B ZA200408777 B ZA 200408777B

Authority

ZA

South Africa

Prior art keywords

agent

subject

peroxiredoxin

tissue

expression

Prior art date

2002-04-23

Links

• Espacenet
• Global Dossier
• Discuss

• 206010029113 Neovascularisation Diseases 0.000 title claims description 63
• 230000008929 regeneration Effects 0.000 title description 40
• 238000011069 regeneration method Methods 0.000 title description 40
• 230000002107 myocardial effect Effects 0.000 title description 39
• 230000006698 induction Effects 0.000 title description 26
• 210000004413 cardiac myocyte Anatomy 0.000 claims description 193
• 210000000130 stem cell Anatomy 0.000 claims description 160
• 210000004027 cell Anatomy 0.000 claims description 154
• 230000003511 endothelial effect Effects 0.000 claims description 154
• 239000003795 chemical substances by application Substances 0.000 claims description 114
• 230000014509 gene expression Effects 0.000 claims description 113
• 108020004999 messenger RNA Proteins 0.000 claims description 105
• 230000006907 apoptotic process Effects 0.000 claims description 101
• 108020004414 DNA Proteins 0.000 claims description 93
• 108030002458 peroxiredoxin Proteins 0.000 claims description 90
• 210000001519 tissue Anatomy 0.000 claims description 89
• 102000007456 Peroxiredoxin Human genes 0.000 claims description 85
• 102100031344 Thioredoxin-interacting protein Human genes 0.000 claims description 78
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 71
• 210000002216 heart Anatomy 0.000 claims description 70
• 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 69
• 101710114149 Thioredoxin-interacting protein Proteins 0.000 claims description 63
• 150000007523 nucleic acids Chemical class 0.000 claims description 62
• 102000039446 nucleic acids Human genes 0.000 claims description 61
• 108020004707 nucleic acids Proteins 0.000 claims description 61
• 230000003197 catalytic effect Effects 0.000 claims description 59
• 230000000694 effects Effects 0.000 claims description 59
• 238000000034 method Methods 0.000 claims description 57
• 230000000302 ischemic effect Effects 0.000 claims description 53
• 230000035755 proliferation Effects 0.000 claims description 52
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 48
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 48
• 210000000648 angioblast Anatomy 0.000 claims description 48
• 210000004165 myocardium Anatomy 0.000 claims description 42
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 41
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 41
• 108060008226 thioredoxin Proteins 0.000 claims description 41
• 108091034117 Oligonucleotide Proteins 0.000 claims description 40
• 102000002933 Thioredoxin Human genes 0.000 claims description 40
• 239000003112 inhibitor Substances 0.000 claims description 40
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 39
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 39
• 229940094937 thioredoxin Drugs 0.000 claims description 39
• 230000004217 heart function Effects 0.000 claims description 37
• 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims description 34
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 31
• 230000001351 cycling effect Effects 0.000 claims description 31
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 30
• 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims description 30
• 208000010125 myocardial infarction Diseases 0.000 claims description 30
• 108090001007 Interleukin-8 Proteins 0.000 claims description 29
• 102000004890 Interleukin-8 Human genes 0.000 claims description 28
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
• 230000004913 activation Effects 0.000 claims description 26
• 239000000074 antisense oligonucleotide Substances 0.000 claims description 26
• 238000012230 antisense oligonucleotides Methods 0.000 claims description 26
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical group C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 25
• 229940096397 interleukin-8 Drugs 0.000 claims description 25
• 230000000747 cardiac effect Effects 0.000 claims description 23
• 230000003993 interaction Effects 0.000 claims description 19
• 150000003384 small molecules Chemical group 0.000 claims description 19
• 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 18
• 230000002401 inhibitory effect Effects 0.000 claims description 18
• 230000032258 transport Effects 0.000 claims description 18
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
• 210000005003 heart tissue Anatomy 0.000 claims description 17
• 238000013519 translation Methods 0.000 claims description 16
• 108050006947 CXC Chemokine Proteins 0.000 claims description 15
• 102000019388 CXC chemokine Human genes 0.000 claims description 15
• 102000019034 Chemokines Human genes 0.000 claims description 15
• 108010012236 Chemokines Proteins 0.000 claims description 15
• 206010019280 Heart failures Diseases 0.000 claims description 15
• 238000004519 manufacturing process Methods 0.000 claims description 15
• 102000016950 Chemokine CXCL1 Human genes 0.000 claims description 14
• 208000035475 disorder Diseases 0.000 claims description 14
• 108010014419 Chemokine CXCL1 Proteins 0.000 claims description 13
• 102000008186 Collagen Human genes 0.000 claims description 13
• 108010035532 Collagen Proteins 0.000 claims description 13
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 13
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 13
• 229920001436 collagen Polymers 0.000 claims description 13
• 208000031225 myocardial ischemia Diseases 0.000 claims description 12
• 210000004351 coronary vessel Anatomy 0.000 claims description 11
• 239000003814 drug Substances 0.000 claims description 11
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
• 230000015572 biosynthetic process Effects 0.000 claims description 9
• 230000009368 gene silencing by RNA Effects 0.000 claims description 9
• 230000001023 pro-angiogenic effect Effects 0.000 claims description 9
• 241000124008 Mammalia Species 0.000 claims description 8
• 239000000411 inducer Substances 0.000 claims description 8
• 102000053602 DNA Human genes 0.000 claims description 7
• 108091030071 RNAI Proteins 0.000 claims description 7
• 238000010494 dissociation reaction Methods 0.000 claims description 7
• 230000005593 dissociations Effects 0.000 claims description 7
• 210000002950 fibroblast Anatomy 0.000 claims description 7
• 230000001939 inductive effect Effects 0.000 claims description 7
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
• 101710082961 GATA-binding factor 2 Proteins 0.000 claims description 6
• 102000004316 Oxidoreductases Human genes 0.000 claims description 6
• 108090000854 Oxidoreductases Proteins 0.000 claims description 6
• 108091028664 Ribonucleotide Proteins 0.000 claims description 6
• 239000002336 ribonucleotide Substances 0.000 claims description 6
• 125000002652 ribonucleotide group Chemical group 0.000 claims description 6
• 230000002792 vascular Effects 0.000 claims description 6
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
• 210000005240 left ventricle Anatomy 0.000 claims description 5
• 239000000203 mixture Substances 0.000 claims description 5
• 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 4
• 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 4
• 102000001902 CC Chemokines Human genes 0.000 claims description 4
• 108010040471 CC Chemokines Proteins 0.000 claims description 4
• 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims description 4
• 108010071382 NF-E2-Related Factor 2 Proteins 0.000 claims description 4
• 108010012822 Peroxiredoxin III Proteins 0.000 claims description 4
• 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims description 4
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 4
• 102100040120 Prominin-1 Human genes 0.000 claims description 4
• 102100034769 Thioredoxin-dependent peroxide reductase, mitochondrial Human genes 0.000 claims description 4
• 230000000735 allogeneic effect Effects 0.000 claims description 4
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
• 210000004072 lung Anatomy 0.000 claims description 4
• 229920002477 rna polymer Polymers 0.000 claims description 4
• 210000002460 smooth muscle Anatomy 0.000 claims description 4
• 150000003573 thiols Chemical class 0.000 claims description 4
• 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 3
• 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 3
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 3
• 229940126864 fibroblast growth factor Drugs 0.000 claims description 3
• 210000002064 heart cell Anatomy 0.000 claims description 3
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
• 210000004969 inflammatory cell Anatomy 0.000 claims description 3
• 210000001161 mammalian embryo Anatomy 0.000 claims description 3
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 3
• 230000003836 peripheral circulation Effects 0.000 claims description 3
• 210000002027 skeletal muscle Anatomy 0.000 claims description 3
• 210000004881 tumor cell Anatomy 0.000 claims description 3
• WVLHHLRVNDMIAR-IBGZPJMESA-N AMD 070 Chemical group C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 claims description 2
• 206010002383 Angina Pectoris Diseases 0.000 claims description 2
• 102000009840 Angiopoietins Human genes 0.000 claims description 2
• 108010009906 Angiopoietins Proteins 0.000 claims description 2
• 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 2
• 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 2
• 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 2
• 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 2
• 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
• 108010055166 Chemokine CCL5 Proteins 0.000 claims description 2
• 102100023688 Eotaxin Human genes 0.000 claims description 2
• 101710139422 Eotaxin Proteins 0.000 claims description 2
• 101710121996 Hexon protein p72 Proteins 0.000 claims description 2
• 102100024573 Macrophage-capping protein Human genes 0.000 claims description 2
• 101710125418 Major capsid protein Proteins 0.000 claims description 2
• 239000002870 angiogenesis inducing agent Substances 0.000 claims description 2
• 210000005013 brain tissue Anatomy 0.000 claims description 2
• 230000004663 cell proliferation Effects 0.000 claims description 2
• 230000002490 cerebral effect Effects 0.000 claims description 2
• 239000005547 deoxyribonucleotide Substances 0.000 claims description 2
• 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
• 210000003754 fetus Anatomy 0.000 claims description 2
• 238000009472 formulation Methods 0.000 claims description 2
• 230000002496 gastric effect Effects 0.000 claims description 2
• 230000002440 hepatic effect Effects 0.000 claims description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical group C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
• 229960002411 imatinib Drugs 0.000 claims description 2
• 230000003834 intracellular effect Effects 0.000 claims description 2
• AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 2
• 230000001537 neural effect Effects 0.000 claims description 2
• 230000002093 peripheral effect Effects 0.000 claims description 2
• YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims description 2
• 229960002169 plerixafor Drugs 0.000 claims description 2
• 210000005084 renal tissue Anatomy 0.000 claims description 2
• 210000005241 right ventricle Anatomy 0.000 claims description 2
• 210000003699 striated muscle Anatomy 0.000 claims description 2
• 210000005166 vasculature Anatomy 0.000 claims 2
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
• 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 claims 1
• 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 claims 1
• 241000700159 Rattus Species 0.000 description 172
• 206010061216 Infarction Diseases 0.000 description 103
• 108090000623 proteins and genes Proteins 0.000 description 67
• 210000001185 bone marrow Anatomy 0.000 description 63
• 102000004190 Enzymes Human genes 0.000 description 61
• 108090000790 Enzymes Proteins 0.000 description 61
• 241001465754 Metazoa Species 0.000 description 53
• 238000002347 injection Methods 0.000 description 46
• 239000007924 injection Substances 0.000 description 46
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
• 230000007574 infarction Effects 0.000 description 45
• 239000011780 sodium chloride Substances 0.000 description 44
• 210000000107 myocyte Anatomy 0.000 description 34
• 230000001965 increasing effect Effects 0.000 description 33
• 230000006872 improvement Effects 0.000 description 32
• 125000003729 nucleotide group Chemical group 0.000 description 27
• 238000010186 staining Methods 0.000 description 27
• 230000001419 dependent effect Effects 0.000 description 26
• 239000002773 nucleotide Substances 0.000 description 25
• 230000009467 reduction Effects 0.000 description 25
• 238000006722 reduction reaction Methods 0.000 description 25
• 102000004169 proteins and genes Human genes 0.000 description 22
• 208000028867 ischemia Diseases 0.000 description 21
• 230000036542 oxidative stress Effects 0.000 description 20
• 230000002829 reductive effect Effects 0.000 description 20
• 230000003078 antioxidant effect Effects 0.000 description 19
• 230000006870 function Effects 0.000 description 19
• 238000003776 cleavage reaction Methods 0.000 description 18
• 239000003963 antioxidant agent Substances 0.000 description 17
• 238000009396 hybridization Methods 0.000 description 17
• 230000007246 mechanism Effects 0.000 description 17
• 230000007017 scission Effects 0.000 description 17
• 230000014616 translation Effects 0.000 description 17
• 230000002861 ventricular Effects 0.000 description 17
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
• 230000027455 binding Effects 0.000 description 16
• 230000001404 mediated effect Effects 0.000 description 16
• 230000004224 protection Effects 0.000 description 16
• 235000018102 proteins Nutrition 0.000 description 16
• 238000011084 recovery Methods 0.000 description 16
• 235000000346 sugar Nutrition 0.000 description 16
• 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 15
• 101000796022 Homo sapiens Thioredoxin-interacting protein Proteins 0.000 description 15
• 102000013394 Troponin I Human genes 0.000 description 15
• 108010065729 Troponin I Proteins 0.000 description 15
• 235000006708 antioxidants Nutrition 0.000 description 15
• 230000001640 apoptogenic effect Effects 0.000 description 15
• 239000002299 complementary DNA Substances 0.000 description 15
• 210000005260 human cell Anatomy 0.000 description 15
• 230000022131 cell cycle Effects 0.000 description 14
• 238000001727 in vivo Methods 0.000 description 14
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 13
• 230000000875 corresponding effect Effects 0.000 description 13
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
• 238000010253 intravenous injection Methods 0.000 description 13
• 230000005012 migration Effects 0.000 description 13
• 238000013508 migration Methods 0.000 description 13
• 239000002953 phosphate buffered saline Substances 0.000 description 13
• 230000001105 regulatory effect Effects 0.000 description 13
• 230000014621 translational initiation Effects 0.000 description 13
• 230000004862 vasculogenesis Effects 0.000 description 13
• 230000001413 cellular effect Effects 0.000 description 12
• 238000011260 co-administration Methods 0.000 description 12
• 108091081024 Start codon Proteins 0.000 description 11
• 230000001086 cytosolic effect Effects 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 230000003389 potentiating effect Effects 0.000 description 11
• 231100000241 scar Toxicity 0.000 description 11
• 241000894007 species Species 0.000 description 11
• 108091027757 Deoxyribozyme Proteins 0.000 description 10
• 230000001154 acute effect Effects 0.000 description 10
• 239000011616 biotin Substances 0.000 description 10
• 229960002685 biotin Drugs 0.000 description 10
• 230000004069 differentiation Effects 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 238000010790 dilution Methods 0.000 description 9
• 239000012895 dilution Substances 0.000 description 9
• 229910052739 hydrogen Inorganic materials 0.000 description 9
• 239000001257 hydrogen Substances 0.000 description 9
• 230000005764 inhibitory process Effects 0.000 description 9
• 230000010016 myocardial function Effects 0.000 description 9
• 229910052760 oxygen Inorganic materials 0.000 description 9
• 239000001301 oxygen Substances 0.000 description 9
• 230000002441 reversible effect Effects 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 239000000758 substrate Substances 0.000 description 9
• 238000011282 treatment Methods 0.000 description 9
• 108020005038 Terminator Codon Proteins 0.000 description 8
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 8
• 230000033115 angiogenesis Effects 0.000 description 8
• 235000020958 biotin Nutrition 0.000 description 8
• 230000006378 damage Effects 0.000 description 8
• 230000009977 dual effect Effects 0.000 description 8
• 210000002889 endothelial cell Anatomy 0.000 description 8
• 230000003394 haemopoietic effect Effects 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 239000002243 precursor Substances 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 238000003757 reverse transcription PCR Methods 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 8
• 235000005282 vitamin D3 Nutrition 0.000 description 8
• 239000011647 vitamin D3 Substances 0.000 description 8
• 229940021056 vitamin d3 Drugs 0.000 description 8
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
• 108050006400 Cyclin Proteins 0.000 description 7
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
• 230000035605 chemotaxis Effects 0.000 description 7
• 230000008021 deposition Effects 0.000 description 7
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
• 239000007925 intracardiac injection Substances 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 238000002372 labelling Methods 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 7
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 7
• 239000013598 vector Substances 0.000 description 7
• -1 without limitation Chemical class 0.000 description 7
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• 102000007469 Actins Human genes 0.000 description 6
• 108010085238 Actins Proteins 0.000 description 6
• 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 6
• 108010004729 Phycoerythrin Proteins 0.000 description 6
• 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 6
• 101710172405 Thiol peroxidase Proteins 0.000 description 6
• 102000004903 Troponin Human genes 0.000 description 6
• 108090001027 Troponin Proteins 0.000 description 6
• 230000002424 anti-apoptotic effect Effects 0.000 description 6
• 230000025084 cell cycle arrest Effects 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 230000000295 complement effect Effects 0.000 description 6
• 230000001605 fetal effect Effects 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 239000013642 negative control Substances 0.000 description 6
• 230000002265 prevention Effects 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 230000004083 survival effect Effects 0.000 description 6
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 108090001008 Avidin Proteins 0.000 description 5
• 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 5
• 230000006820 DNA synthesis Effects 0.000 description 5
• 102100036912 Desmin Human genes 0.000 description 5
• 108010044052 Desmin Proteins 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 206010021143 Hypoxia Diseases 0.000 description 5
• 102000003992 Peroxidases Human genes 0.000 description 5
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• 230000000903 blocking effect Effects 0.000 description 5
• 210000001054 cardiac fibroblast Anatomy 0.000 description 5
• 101150073031 cdk2 gene Proteins 0.000 description 5
• 238000012512 characterization method Methods 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 210000005045 desmin Anatomy 0.000 description 5
• 230000007954 hypoxia Effects 0.000 description 5
• 238000011065 in-situ storage Methods 0.000 description 5
• 238000002955 isolation Methods 0.000 description 5
• 230000002018 overexpression Effects 0.000 description 5
• 108010044644 pegfilgrastim Proteins 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 238000003752 polymerase chain reaction Methods 0.000 description 5
• 150000008163 sugars Chemical class 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
• 208000035657 Abasia Diseases 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
• 108010029961 Filgrastim Proteins 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
• 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 4
• 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 4
• 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 4
• 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 4
• 102000002791 Interleukin-8B Receptors Human genes 0.000 description 4
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 4
• 108091054437 MHC class I family Proteins 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 108091028043 Nucleic acid sequence Proteins 0.000 description 4
• 101150089457 PAG gene Proteins 0.000 description 4
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 4
• 108091000080 Phosphotransferase Proteins 0.000 description 4
• 102000000395 SH3 domains Human genes 0.000 description 4
• 108050008861 SH3 domains Proteins 0.000 description 4
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
• 108091036066 Three prime untranslated region Proteins 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 230000006369 cell cycle progression Effects 0.000 description 4
• 230000001447 compensatory effect Effects 0.000 description 4
• 239000000562 conjugate Substances 0.000 description 4
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
• 210000000172 cytosol Anatomy 0.000 description 4
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 4
• 229960000301 factor viii Drugs 0.000 description 4
• 229960004177 filgrastim Drugs 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 210000003205 muscle Anatomy 0.000 description 4
• 230000005914 myocardial expression Effects 0.000 description 4
• 239000012188 paraffin wax Substances 0.000 description 4
• 108040007629 peroxidase activity proteins Proteins 0.000 description 4
• 102000020233 phosphotransferase Human genes 0.000 description 4
• 230000008092 positive effect Effects 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 239000011541 reaction mixture Substances 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 230000002195 synergetic effect Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 230000036962 time dependent Effects 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
• QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 108010061299 CXCR4 Receptors Proteins 0.000 description 3
• 102000012000 CXCR4 Receptors Human genes 0.000 description 3
• 108090000994 Catalytic RNA Proteins 0.000 description 3
• 102000053642 Catalytic RNA Human genes 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 108091035707 Consensus sequence Proteins 0.000 description 3
• 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 3
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 108010070675 Glutathione transferase Proteins 0.000 description 3
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 3
• 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 3
• 101000963987 Homo sapiens SH3 domain-binding protein 5 Proteins 0.000 description 3
• 206010020880 Hypertrophy Diseases 0.000 description 3
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 101100298488 Mus musculus Prdx1 gene Proteins 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 102100040119 SH3 domain-binding protein 5 Human genes 0.000 description 3
• 241000251131 Sphyrna Species 0.000 description 3
• 102100027224 Tumor protein p53-inducible nuclear protein 1 Human genes 0.000 description 3
• 108050003317 Tumor protein p53-inducible nuclear protein 1 Proteins 0.000 description 3
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
• 206010000891 acute myocardial infarction Diseases 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 210000002565 arteriole Anatomy 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 230000003416 augmentation Effects 0.000 description 3
• 230000003190 augmentative effect Effects 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 150000001720 carbohydrates Chemical class 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 230000004087 circulation Effects 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 201000010099 disease Diseases 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 238000002592 echocardiography Methods 0.000 description 3
• 210000001671 embryonic stem cell Anatomy 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
• 102000028546 heme binding Human genes 0.000 description 3
• 108091022907 heme binding Proteins 0.000 description 3
• 229940025294 hemin Drugs 0.000 description 3
• BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 3
• 102000048429 human PAG1 Human genes 0.000 description 3
• 230000008595 infiltration Effects 0.000 description 3
• 238000001764 infiltration Methods 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 230000009456 molecular mechanism Effects 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 230000001590 oxidative effect Effects 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 3
• 229960001373 pegfilgrastim Drugs 0.000 description 3
• 230000000861 pro-apoptotic effect Effects 0.000 description 3
• 230000002250 progressing effect Effects 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 238000006479 redox reaction Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000028617 response to DNA damage stimulus Effects 0.000 description 3
• 108091092562 ribozyme Proteins 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
• 229940113082 thymine Drugs 0.000 description 3
• 210000003462 vein Anatomy 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• 201000006474 Brain Ischemia Diseases 0.000 description 2
• 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 2
• 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 2
• 108091008928 CXC chemokine receptors Proteins 0.000 description 2
• 102000054900 CXCR Receptors Human genes 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 206010007558 Cardiac failure chronic Diseases 0.000 description 2
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
• 208000006029 Cardiomegaly Diseases 0.000 description 2
• 102000011727 Caspases Human genes 0.000 description 2
• 108010076667 Caspases Proteins 0.000 description 2
• 108010068192 Cyclin A Proteins 0.000 description 2
• 102100025191 Cyclin-A2 Human genes 0.000 description 2
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
• 230000005778 DNA damage Effects 0.000 description 2
• 231100000277 DNA damage Toxicity 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
• AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
• 102100023471 E-selectin Human genes 0.000 description 2
• 108010067770 Endopeptidase K Proteins 0.000 description 2
• 108060002716 Exonuclease Proteins 0.000 description 2
• 102000001690 Factor VIII Human genes 0.000 description 2
• 108010054218 Factor VIII Proteins 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 102000013382 Gelatinases Human genes 0.000 description 2
• 108010026132 Gelatinases Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
• 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 2
• 101000622123 Homo sapiens E-selectin Proteins 0.000 description 2
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
• 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
• 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 229930010555 Inosine Natural products 0.000 description 2
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
• 108010075639 MAP Kinase Kinase Kinase 5 Proteins 0.000 description 2
• 102000043129 MHC class I family Human genes 0.000 description 2
• 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
• 108091093105 Nuclear DNA Proteins 0.000 description 2
• 101710163270 Nuclease Proteins 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• 102100029139 Peroxiredoxin-1 Human genes 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 108010039230 Protein Kinase C-delta Proteins 0.000 description 2
• 102100037340 Protein kinase C delta type Human genes 0.000 description 2
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
• 238000010240 RT-PCR analysis Methods 0.000 description 2
• 101000746366 Rattus norvegicus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
• 108700009124 Transcription Initiation Site Proteins 0.000 description 2
• 102000004357 Transferases Human genes 0.000 description 2
• 108090000992 Transferases Proteins 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 108010091356 Tumor Protein p73 Proteins 0.000 description 2
• 102000018252 Tumor Protein p73 Human genes 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
• 208000033774 Ventricular Remodeling Diseases 0.000 description 2
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000000996 additive effect Effects 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 125000000217 alkyl group Chemical group 0.000 description 2
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 210000002798 bone marrow cell Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 238000010804 cDNA synthesis Methods 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 230000011712 cell development Effects 0.000 description 2
• 230000007248 cellular mechanism Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000002975 chemoattractant Substances 0.000 description 2
• 230000003399 chemotactic effect Effects 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000000205 computational method Methods 0.000 description 2
• 238000004624 confocal microscopy Methods 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 230000001186 cumulative effect Effects 0.000 description 2
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 229940104302 cytosine Drugs 0.000 description 2
• 239000000824 cytostatic agent Substances 0.000 description 2
• 230000001085 cytostatic effect Effects 0.000 description 2
• 238000010217 densitometric analysis Methods 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 238000002224 dissection Methods 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 102000013165 exonuclease Human genes 0.000 description 2
• 210000004700 fetal blood Anatomy 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• 229930182830 galactose Natural products 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 230000004153 glucose metabolism Effects 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 102000053523 human CXCR4 Human genes 0.000 description 2
• 102000046661 human PECAM1 Human genes 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000002055 immunohistochemical effect Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 229960003786 inosine Drugs 0.000 description 2
• 238000010212 intracellular staining Methods 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 210000003470 mitochondria Anatomy 0.000 description 2
• 210000005087 mononuclear cell Anatomy 0.000 description 2
• 230000030248 negative regulation of fibroblast proliferation Effects 0.000 description 2
• 229940071846 neulasta Drugs 0.000 description 2
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
• 230000005937 nuclear translocation Effects 0.000 description 2
• 230000006911 nucleation Effects 0.000 description 2
• 238000010899 nucleation Methods 0.000 description 2
• 230000010412 perfusion Effects 0.000 description 2
• 210000003516 pericardium Anatomy 0.000 description 2
• DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 229920000768 polyamine Polymers 0.000 description 2
• 229920000728 polyester Polymers 0.000 description 2
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000003651 pro-proliferative effect Effects 0.000 description 2
• 108700043101 rat CXCL12 Proteins 0.000 description 2
• 239000003642 reactive oxygen metabolite Substances 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• 230000027756 respiratory electron transport chain Effects 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000036573 scar formation Effects 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 239000005495 thyroid hormone Substances 0.000 description 2
• 229940036555 thyroid hormone Drugs 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 230000000982 vasogenic effect Effects 0.000 description 2
• 108010047303 von Willebrand Factor Proteins 0.000 description 2
• 102100036537 von Willebrand factor Human genes 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
• GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
• YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
• VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
• WJBNIBFTNGZFBW-DJLDLDEBSA-N 2'-deoxynebularine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 WJBNIBFTNGZFBW-DJLDLDEBSA-N 0.000 description 1
• KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
• HDZZVAMISRMYHH-UHFFFAOYSA-N 2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
• JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• 108020003589 5' Untranslated Regions Proteins 0.000 description 1
• IHHSSHCBRVYGJX-UHFFFAOYSA-N 6-chloro-2-methoxyacridin-9-amine Chemical compound C1=C(Cl)C=CC2=C(N)C3=CC(OC)=CC=C3N=C21 IHHSSHCBRVYGJX-UHFFFAOYSA-N 0.000 description 1
• VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical class NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
• CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
• NQAZHXBSLFDVKM-KVQBGUIXSA-N 9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-2,6-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 NQAZHXBSLFDVKM-KVQBGUIXSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 108091007065 BIRCs Proteins 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
• 108091007914 CDKs Proteins 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
• 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
• 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
• 102000009410 Chemokine receptor Human genes 0.000 description 1
• 108050000299 Chemokine receptor Proteins 0.000 description 1
• 239000004380 Cholic acid Substances 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 102000016736 Cyclin Human genes 0.000 description 1
• 102100030497 Cytochrome c Human genes 0.000 description 1
• 108010075031 Cytochromes c Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102100030013 Endoribonuclease Human genes 0.000 description 1
• 101710199605 Endoribonuclease Proteins 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 206010063560 Excessive granulation tissue Diseases 0.000 description 1
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
• 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
• 108091027874 Group I catalytic intron Proteins 0.000 description 1
• 208000000435 Heart Rupture Diseases 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
• 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
• 241000724709 Hepatitis delta virus Species 0.000 description 1
• 101000916059 Homo sapiens C-X-C chemokine receptor type 2 Proteins 0.000 description 1
• 101100441536 Homo sapiens CXCR1 gene Proteins 0.000 description 1
• 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
• 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
• 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
• 101000584845 Homo sapiens Tumor protein p73 Proteins 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000014429 Insulin-like growth factor Human genes 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
• 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
• 101710164337 Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101001055056 Mus musculus Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
• 102000004364 Myogenin Human genes 0.000 description 1
• 108010056785 Myogenin Proteins 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 241000221960 Neurospora Species 0.000 description 1
• 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 1
• 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108700020962 Peroxidase Proteins 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 239000004721 Polyphenylene oxide Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 241000723554 Pontia occidentalis Species 0.000 description 1
• WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 101150035060 Prx gene Proteins 0.000 description 1
• 108091034057 RNA (poly(A)) Proteins 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 101100383168 Rattus norvegicus Cdkn2b gene Proteins 0.000 description 1
• 101000885869 Rattus norvegicus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
• 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 208000009982 Ventricular Dysfunction Diseases 0.000 description 1
• 206010060953 Ventricular failure Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 150000001251 acridines Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000002431 aminoalkoxy group Chemical group 0.000 description 1
• 125000005122 aminoalkylamino group Chemical group 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 229930185229 antidesmin Natural products 0.000 description 1
• 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• 229910052793 cadmium Inorganic materials 0.000 description 1
• BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
• 229960005084 calcitriol Drugs 0.000 description 1
• GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
• 125000001369 canonical nucleoside group Chemical group 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 239000000298 carbocyanine Substances 0.000 description 1
• 230000005961 cardioprotection Effects 0.000 description 1
• 230000003293 cardioprotective effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 108020001778 catalytic domains Proteins 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000034196 cell chemotaxis Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 239000005482 chemotactic factor Substances 0.000 description 1
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
• BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
• 235000019416 cholic acid Nutrition 0.000 description 1
• 229960002471 cholic acid Drugs 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 210000002358 circulating endothelial cell Anatomy 0.000 description 1
• 229910017052 cobalt Inorganic materials 0.000 description 1
• 239000010941 cobalt Substances 0.000 description 1
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
• 229940096422 collagen type i Drugs 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 239000005289 controlled pore glass Substances 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
• VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000005546 dideoxynucleotide Substances 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• 150000004662 dithiols Chemical class 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 229960002143 fluorescein Drugs 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 210000001126 granulation tissue Anatomy 0.000 description 1
• 244000144993 groups of animals Species 0.000 description 1
• 150000003278 haem Chemical class 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000003566 hemangioblast Anatomy 0.000 description 1
• 125000004404 heteroalkyl group Chemical group 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• 150000002402 hexoses Chemical class 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 230000009097 homeostatic mechanism Effects 0.000 description 1
• 102000055357 human CXCR2 Human genes 0.000 description 1
• AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000000222 hyperoxic effect Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 210000002570 interstitial cell Anatomy 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
• 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000025608 mitochondrion localization Effects 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 230000032929 negative regulation of cell cycle Effects 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 230000030648 nucleus localization Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 230000004792 oxidative damage Effects 0.000 description 1
• 150000002926 oxygen Chemical class 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 239000000863 peptide conjugate Substances 0.000 description 1
• LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000008298 phosphoramidates Chemical class 0.000 description 1
• 150000003014 phosphoric acid esters Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920000570 polyether Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 229940124606 potential therapeutic agent Drugs 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 229960000286 proflavine Drugs 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical class C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000002601 radiography Methods 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000008943 replicative senescence Effects 0.000 description 1
• 230000008458 response to injury Effects 0.000 description 1
• 230000011506 response to oxidative stress Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 230000005476 size effect Effects 0.000 description 1
• 230000022379 skeletal muscle tissue development Effects 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 238000005987 sulfurization reaction Methods 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• XXYIANZGUOSQHY-XLPZGREQSA-N thymidine 3'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)C1 XXYIANZGUOSQHY-XLPZGREQSA-N 0.000 description 1
• 239000010936 titanium Substances 0.000 description 1
• 229910052719 titanium Inorganic materials 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 101150072359 trx gene Proteins 0.000 description 1
• 239000000225 tumor suppressor protein Substances 0.000 description 1
• 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
• 230000009452 underexpressoin Effects 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
• 230000006815 ventricular dysfunction Effects 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1